Professional background

Asim is a consultant haematologist at UCLH and professor of haematology in the UCL Cancer Institute. He was an undergraduate at Guy's Hospital Medical School in London and obtained his specialist training in haematology at the Middlesex and University College Hospitals.

He previously received clinician scientist and senior clinical fellowships from the Medical Research Council for doctoral and post-doctoral research work.

He is lead clinician for adult acute leukaemia at UCLH and is a member of the National Cancer Research Institute Acute Myeloid Leukaemia working group and of the Blood Cancer UK new clinical trials committee.

Research interests

Acute leukaemias, myelodysplasia

Languages spoken



Selected recent publications. For a full list, please see

Vanhaesebroeck, B. and A. Khwaja, PI3Kdelta Inhibition Hits a Sensitive Spot in B Cell Malignancies. Cancer Cell, 2014. 25(3): p. 269-71.

Linch, D.C., et al Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia: implications for consolidation therapy. Blood. 2014 124:273-6.

Burnett A, et al. A Randomised Comparison of the Novel Nucleoside Analogue Sapacitabine with Low Dose Cytarabine in Older patients with Acute Myeloid Leukaemia. Leukemia. 2015 Jun;29(6):1312-9.

Burnett AK, et al UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1295-305.

Burnett A, et al Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3mg/m2 with 6mg/m2 in the NCRI AML17 trial. Haematologica. 2016 Jun;101(6):724-31.

Khwaja A, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016 Mar 10;2:16010.

Freeman SD, et al Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. J Clin Oncol. 2018 May 20;36(15):1486-1497.

Burnett AK, et al The Addition of the mTOR Inhibitor, Everolimus, to Consolidation Therapy in Acute Myeloid Leukaemia: Experience from the UK NCRI AML17 Trial. Haematologica. 2018 Oct;103(10):1654-1661.

Sellar R, et al Comparative Analysis of T-cell deplete Melphalan versus Busulphan Reduced intensity Conditioning Unrelated Donor Stem Cell Transplantation for Acute Myeloid Leukaemia Br J Haematol. 2019 Oct;187(1):e20-e24.

Dillon R, et al. Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study. Blood. 2020;135(9):680-688.

Fox TA, et al Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol. 2020 Jul 17. doi: 10.1111/bjh.17027.